Heart failure affects an estimated 64.3 million people worldwide
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Subscribe To Our Newsletter & Stay Updated